[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 1165
1. Razmkhah M, Jaberipour M, Ghaderi A: Downregulation of MMP2 and Bcl-2 in Adipose Derived Stem Cells (ASCs) following Transfection with IP-10 Gene. Avicenna J Med Biotechnol; 2014 Jan;6(1):27-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of MMP2 and Bcl-2 in Adipose Derived Stem Cells (ASCs) following Transfection with IP-10 Gene.
  • It is believed that balance between the expression of angiogenic and anti-angiogenic factors, such as SDF-1 and IP-10, may regulate neovascularization within the tumor.
  • METHODS: In this study, we compared the expression of important tumor promoting mediators in IP-10-transfected Adipose Derived Stem Cells (ASCs) to those transfected with SDF-1.
  • ASCs were isolated from adipose tissue of a normal subject undergoing cosmetic mamoplasty surgery using collagenase.
  • CONCLUSION: Anti-angiogenic chemokines such as IP-10 may modulate tumor promoting properties of ASCs and would be introduced as novel candidates for tumor immunotherapy; however, further studies are needed to be conducted.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24551432.001).
  • [ISSN] 2008-2835
  • [Journal-full-title] Avicenna journal of medical biotechnology
  • [ISO-abbreviation] Avicenna J Med Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3895576
  • [Keywords] NOTNLM ; Adipose derived stem cells / IP-10 / SDF-1 / Transfection / Tumor immunotherapy
  •  go-up   go-down


2. Penna F, Busquets S, Toledo M, Pin F, Massa D, López-Soriano FJ, Costelli P, Argilés JM: Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. J Lipid Res; 2013 Nov;54(11):3045-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models.
  • The results clearly show that, in addition to the improvement of the hematocrit, EPO treatment promoted a partial preservation of adipose tissue while exerting negligible effects on muscle loss.
  • Administration of EPO to tumor-bearing animals resulted in a significant increase of lipoprotein lipase (LPL) activity in adipose tissue, suggesting that the treatment favored triacylglycerol (TAG) accumulation in the adipose tissue.
  • In vitro experiments using both adipose tissue slices and 3T3-L1 adipocytes suggests that EPO is able to increase the lipogenic rate through the activation of its specific receptor (EPOR).
  • [MeSH-major] Adipose Tissue / drug effects. Adipose Tissue / pathology. Cachexia / complications. Cachexia / pathology. Erythropoietin / administration & dosage. Erythropoietin / pharmacology. Neoplasms / complications
  • [MeSH-minor] 3T3-L1 Cells. Animals. Cell Differentiation / drug effects. Cell Proliferation / drug effects. Disease Models, Animal. Male. Mice. Muscle, Skeletal / drug effects. Muscle, Skeletal / pathology. Rats. Receptors, Erythropoietin / metabolism

  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2010;5(10):e13604 [21048967.001]
  • [Cites] Blood. 2010 May 27;115(21):4254-63 [20124514.001]
  • [Cites] Science. 2011 Jul 8;333(6039):233-8 [21680814.001]
  • [Cites] Curr Opin Support Palliat Care. 2011 Dec;5(4):356-60 [21934502.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39754-61 [10995753.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Lancet Oncol. 2000 Nov;1:138-47 [11905651.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1072-9 [12942577.001]
  • [Cites] Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S [15050883.001]
  • [Cites] Cancer. 2004 May 1;100(9):1967-77 [15112279.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6855-64 [15501962.001]
  • [Cites] Cancer Res. 1975 Apr;35(4):939-45 [1116151.001]
  • [Cites] J Lipid Res. 1976 Sep;17(5):536-41 [9464.001]
  • [Cites] Biochem J. 1985 Nov 15;232(1):229-36 [4084231.001]
  • [Cites] Nucleic Acids Res. 1991 Jul 25;19(14):3843-8 [1650452.001]
  • [Cites] Arch Biochem Biophys. 1993 Oct;306(1):52-8 [8215420.001]
  • [Cites] Mol Cell Biochem. 1995 Feb 23;143(2):113-8 [7596346.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 1):E656-60 [9142888.001]
  • [Cites] Cancer Lett. 1997 Jun 24;116(2):159-65 [9215859.001]
  • [Cites] Kidney Int Suppl. 1999 Jul;71:S213-5 [10412779.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Biochem Z. 1959;332:18-46 [14402528.001]
  • [Cites] Cancer. 2005 May 15;103(10):2189-98 [15822132.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):31-41 [16314085.001]
  • [Cites] Eur J Haematol. 2007 Mar;78(3):183-205 [17253966.001]
  • [Cites] CA Cancer J Clin. 2007 Jul-Aug;57(4):225-41 [17626119.001]
  • [Cites] Med Hypotheses. 2008;70(6):1167-73 [18180110.001]
  • [Cites] J Orthop Res. 2008 Dec;26(12):1618-26 [18634017.001]
  • [Cites] Clin Nutr. 2010 Apr;29(2):154-9 [20060626.001]
  • [Cites] PLoS One. 2010;5(11):e13986 [21085572.001]
  • (PMID = 23966665.001).
  • [ISSN] 1539-7262
  • [Journal-full-title] Journal of lipid research
  • [ISO-abbreviation] J. Lipid Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Erythropoietin; 11096-26-7 / Erythropoietin
  • [Other-IDs] NLM/ PMC3793608
  • [Keywords] NOTNLM ; anemia / lipogenesis / lipolysis / lipoprotein lipase
  •  go-up   go-down


3. Park J, Park S, Song C, Hong JH, Kim CS, Ahn H: Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma. World J Urol; 2014 Feb;32(1):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To elucidate the reasons for conflicting results regarding the prognostic significance of tumor location in upper tract urothelial carcinoma (UTUC), we analyzed the stage-specific impact of tumor location on oncological outcomes following radical nephroureterectomy (RNU).
  • METHODS: Data from 392 patients who underwent RNU with curative intent between 1991 and 2010 were reviewed.
  • Prognostic impact of tumor location and various clinicopathological factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) was evaluated using Kaplan-Meier and Cox regression analyses at each pathological stage.
  • Tumor location was classified as renal pelvis or ureter, and pT3 tumors were further stratified as invading the renal parenchyma or peripelvic or periureteral fat.
  • RESULTS: In stage-specific analysis, tumor location did not have prognostic significance in patients with ≤pT2 tumors, whereas RFS and CSS rates were significantly lower in patients with pT3 ureteral tumors than renal pelvic tumors.
  • Subgroup analysis showed that RFS and CSS rates were significantly higher for pT3 tumors invading the renal parenchyma than the peripelvic or periureteral fat.
  • On multivariate analysis in pT3 tumors adjusting other clinicopathological parameters, tumor location remained significant predictors for both RFS and CSS.
  • Compared with tumors invading renal parenchyma, tumors invading peripelvic fat or periureteral fat were associated with about 3.5 times higher risk for cancer-specific mortality (p < 0.05).
  • Conflicting institutional results regarding tumor location in UTUC may be due to difference in the proportions of parenchymal versus peripelvic fat invasion in pT3 pelvic tumors.
  • [MeSH-major] Adipose Tissue / pathology. Kidney / pathology. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Ureter / pathology. Urologic Neoplasms / mortality. Urologic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Body Fat Distribution. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Nephrectomy. Prognosis. Regression Analysis. Retrospective Studies. Survival Rate. Treatment Outcome. Ureteroscopy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2012 Mar 13;106(6):1083-8 [22374463.001]
  • [Cites] World J Urol. 2011 Aug;29(4):487-94 [21249372.001]
  • [Cites] J Urol. 2009 Sep;182(3):894-9 [19616243.001]
  • [Cites] Eur Urol. 2012 Jul;62(1):100-14 [22381168.001]
  • [Cites] BJU Int. 2009 Feb;103(3):307-11 [18990163.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Cancer. 2007 Oct 15;110(8):1715-22 [17724728.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5552-64 [17158541.001]
  • [Cites] Eur Urol. 2012 Oct;62(4):677-84 [22349570.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2903-10 [15753461.001]
  • [Cites] World J Urol. 2013 Feb;31(1):189-97 [23229227.001]
  • [Cites] J Urol. 2006 Jul;176(1):48-52 [16753365.001]
  • [Cites] World J Urol. 2009 Apr;27(2):277-83 [19020879.001]
  • [Cites] BJU Int. 2011 Apr;107(7):1059-64 [20825397.001]
  • [Cites] Eur Urol. 2010 Jun;57(6):1072-9 [19619934.001]
  • [Cites] Eur Urol. 2012 Aug;62(2):224-31 [22285763.001]
  • [Cites] J Urol. 2007 Aug;178(2):446-50, dicussion 450 [17561129.001]
  • [Cites] Urol Oncol. 2012 Sep;30(5):666-72 [20933445.001]
  • [Cites] Eur Urol. 2011 Apr;59(4):584-94 [21269756.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):738-43 [10505034.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • [Cites] Eur Urol. 2012 Feb;61(2):245-53 [21975249.001]
  • [Cites] J Urol. 2007 May;177(5):1715-20 [17437794.001]
  • [Cites] BJU Int. 2012 Jul;110(2 Pt 2):E7-13 [22177329.001]
  • [Cites] BJU Int. 2010 Mar;105(6):799-804 [19725824.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3150-6 [12115347.001]
  • [Cites] Eur Urol. 2010 Oct;58(4):574-80 [20637540.001]
  • [Cites] J Urol. 2009 Nov;182(5):2177-81 [19758662.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Eur Urol. 2011 Dec;60(6):1258-65 [21665356.001]
  • (PMID = 23568447.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Markelic M, Velickovic K, Golic I, Otasevic V, Stancic A, Jankovic A, Vucetic M, Buzadzic B, Korac B, Korac A: Endothelial cell apoptosis in brown adipose tissue of rats induced by hyperinsulinaemia: the possible role of TNF-α. Eur J Histochem; 2011;55(4):e34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial cell apoptosis in brown adipose tissue of rats induced by hyperinsulinaemia: the possible role of TNF-α.
  • The aim of the present study was to investigate whether hyperinsulinaemia, which frequently precedes insulin resistance syndrome (obesity, diabetes), induces apoptosis of endothelial cells (ECs) in brown adipose tissue (BAT) and causes BAT atrophy and also, to investigate the possible mechanisms underlying ECs death.
  • Examinations at ultrastructural level showed apoptotic changes of ECs, allowing us to point out that changes mainly but not exclusively, occur in nuclei.
  • Immunohistochemical localization of tumor necrosis factor-alpha (TNF-α) revealed increased expression in ECs of BAT of hyperinsulinaemic animals, indicating its possible role in insulin-induced apoptotic changes.
  • [MeSH-major] Adipocytes / cytology. Adipose Tissue, Brown. Apoptosis. Endothelial Cells / cytology. Hyperinsulinism. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26602-14 [16809344.001]
  • [Cites] Eur J Pharmacol. 2006 Nov 21;550(1-3):134-42 [17026986.001]
  • [Cites] Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):423-36 [16506274.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4903-10 [17018657.001]
  • [Cites] N Engl J Med. 2009 Apr 9;360(15):1509-17 [19357406.001]
  • [Cites] J Biol Chem. 2009 Oct 2;284(40):27090-100 [19654321.001]
  • [Cites] Microcirculation. 2007 Jun-Jul;14(4-5):403-38 [17613811.001]
  • [Cites] Physiology (Bethesda). 2007 Aug;22:252-60 [17699878.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2362-8 [17786229.001]
  • [Cites] Diabetes. 2007 Oct;56(10):2511-22 [17601987.001]
  • [Cites] Nat Rev Drug Discov. 2010 Feb;9(2):107-15 [20118961.001]
  • [Cites] Mol Cell Endocrinol. 2010 Apr 29;318(1-2):2-9 [19686803.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):402-9 [10669636.001]
  • [Cites] Chest. 2000 Mar;117(3):841-54 [10713015.001]
  • [Cites] Ageing Res Rev. 2010 Apr;9(2):142-52 [19619671.001]
  • [Cites] Aging Cell. 2010 Oct;9(5):667-84 [20701600.001]
  • [Cites] Diabetes. 2010 Nov;59(11):2755-63 [20713685.001]
  • [Cites] Cell Metab. 2011 Mar 2;13(3):294-307 [21356519.001]
  • [Cites] Mol Cell Endocrinol. 2011 Jun 6;339(1-2):105-13 [21501656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8033-8 [10884431.001]
  • [Cites] Diabetes. 2000 May;49(5):684-7 [10905473.001]
  • [Cites] Chin Med J (Engl). 2000 Oct;113(10):903-6 [11775837.001]
  • [Cites] Circulation. 2002 Feb 5;105(5):576-82 [11827922.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10730-5 [12149466.001]
  • [Cites] Endocrinology. 2003 Dec;144(12):5390-401 [14500576.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1710-1 [14657487.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S53-5 [14704746.001]
  • [Cites] Diabetes. 2004 Jun;53(6):1418-23 [15161743.001]
  • [Cites] J Histochem Cytochem. 1970 Feb;18(2):116-9 [5415490.001]
  • [Cites] Can J Physiol Pharmacol. 1979 Mar;57(3):257-70 [445227.001]
  • [Cites] Physiol Rev. 1979 Oct;59(4):1078-1104 [386395.001]
  • [Cites] J Clin Invest. 1982 Jun;69(6):1321-36 [6123523.001]
  • [Cites] Am J Physiol. 1982 Jun;242(6):E353-9 [6953766.001]
  • [Cites] Br J Cancer. 1984 Apr;49(4):405-13 [6201181.001]
  • [Cites] Anat Embryol (Berl). 1985;173(2):215-23 [4083523.001]
  • [Cites] Am J Anat. 1988 Jul;182(3):283-93 [3213825.001]
  • [Cites] Annu Rev Immunol. 1989;7:625-55 [2540776.001]
  • [Cites] Am J Cardiol. 1993 Feb 15;71(5):448-50 [8430638.001]
  • [Cites] Jpn J Physiol. 1993;43(2):117-39 [8355416.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26055-8 [8253716.001]
  • [Cites] Life Sci. 1994;54(1):17-25 [8255165.001]
  • [Cites] Nature. 1993 Dec 23-30;366(6457):740-2 [8264795.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4854-8 [8197147.001]
  • [Cites] Annu Rev Med. 1994;45:491-503 [8198398.001]
  • [Cites] Am J Physiol. 1994 Aug;267(2 Pt 1):E187-202 [8074198.001]
  • [Cites] Development. 1994 Dec;120(12):3395-403 [7821211.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2409-15 [7738205.001]
  • [Cites] Endocr Rev. 1995 Apr;16(2):164-76 [7781592.001]
  • [Cites] FASEB J. 1995 Jul;9(10):926-33 [7615161.001]
  • [Cites] Diabetes. 1995 Nov;44(11):1266-73 [7589822.001]
  • [Cites] Science. 1996 Feb 2;271(5249):665-8 [8571133.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Microcirculation. 1996 Jun;3(2):143-65 [8839437.001]
  • [Cites] J Struct Biol. 1997 Feb;118(1):63-72 [9087915.001]
  • [Cites] Microcirculation. 1997 Jun;4(2):211-32 [9219215.001]
  • [Cites] FEBS Lett. 1997 Aug 11;413(1):124-8 [9287129.001]
  • [Cites] JAMA. 1997 Oct 8;278(14):1169-75 [9326477.001]
  • [Cites] Nature. 1997 Oct 9;389(6651):610-4 [9335502.001]
  • [Cites] FEBS Lett. 1997 Oct 27;416(3):324-8 [9373178.001]
  • [Cites] Diabetes. 1997 Dec;46(12):1939-44 [9392477.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 1):L379-88 [9700100.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1683-6 [9733517.001]
  • [Cites] Circulation. 1998 Sep 22;98(12):1153-7 [9743504.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4730-41 [9845539.001]
  • [Cites] J Cell Physiol. 1999 Mar;178(3):359-70 [9989782.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1999;107(2):119-25 [10320052.001]
  • [Cites] Am J Physiol. 1964 Jan;206:143-8 [14117643.001]
  • [Cites] J Lipid Res. 2005 Nov;46(11):2347-55 [16150820.001]
  • [Cites] Circulation. 2006 Apr 18;113(15):1888-904 [16618833.001]
  • [Cites] Diabetes. 2006 May;55(5):1436-42 [16644702.001]
  • (PMID = 22297440.001).
  • [ISSN] 2038-8306
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC3284236
  •  go-up   go-down


5. Mei H, González S, Nakatsu MN, Baclagon ER, Chen FV, Deng SX: Human adipose-derived stem cells support the growth of limbal stem/progenitor cells. PLoS One; 2017;12(10):e0186238
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human adipose-derived stem cells support the growth of limbal stem/progenitor cells.
  • To reduce possible xenobiotic contamination from 3T3s, primary human adipose-derived stem cells (ASCs) were examined as feeder cells to support the expansion of LSCs in vitro.
  • The expanded LSCs were examined at the end of a 2-week culture.
  • In conclusion, ASCs support the growth of LSCs in the form of cell clusters but not in single cells.
  • [MeSH-major] Adipose Tissue / cytology. Limbus Corneae / cytology. Stem Cells / cytology
  • [MeSH-minor] 3T3 Cells. Adult. Aged. Animals. Biomarkers / metabolism. Cell Aggregation. Cell Communication. Cell Count. Cell Differentiation. Cell Proliferation. Cells, Cultured. Epithelial Cells / cytology. Epithelial Cells / metabolism. Feeder Cells / cytology. Humans. Immunohistochemistry. Mice. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cornea. 2010 May;29(5):502-9 [20299977.001]
  • [Cites] Tissue Eng Part C Methods. 2011 May;17(5):537-48 [21175372.001]
  • [Cites] Cytotherapy. 2013 Jun;15(6):641-8 [23570660.001]
  • [Cites] Ophthalmology. 1990 Apr;97(4):446-55 [1691476.001]
  • [Cites] Ophthalmology. 2002 Aug;109(8):1547-52 [12153809.001]
  • [Cites] Ocul Surf. 2016 Apr;14 (2):113-20 [26804252.001]
  • [Cites] Nat Med. 2005 Feb;11(2):228-32 [15685172.001]
  • [Cites] Exp Eye Res. 2013 Nov;116:169-76 [24016868.001]
  • [Cites] J Cell Mol Med. 2008 Aug;12(4):1303-16 [18318692.001]
  • [Cites] J Cell Biol. 1986 Jul;103(1):49-62 [2424919.001]
  • [Cites] Regen Med. 2013 Sep;8(5):553-67 [23725042.001]
  • [Cites] Am J Ophthalmol. 2000 Oct;130(4):543 [11024443.001]
  • [Cites] Cytometry A. 2014 Jan;85(1):43-77 [24700575.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2014 Oct 02;55(10):6953-9 [25277234.001]
  • [Cites] Cell. 1989 Apr 21;57(2):201-9 [2702690.001]
  • [Cites] Nat Rev Genet. 2012 Mar 13;13(4):227-32 [22411467.001]
  • [Cites] Stem Cell Res. 2016 Mar;16(2):358-64 [26896856.001]
  • [Cites] Stem Cells. 2005;23 (1):63-73 [15625123.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1991 Jan;32(1):96-105 [1702774.001]
  • [Cites] J Virol. 2011 Sep;85(17):9247-8 [21697491.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1987 Sep;28(9):1450-6 [3623831.001]
  • [Cites] Tissue Eng Part C Methods. 2014 May;20(5):393-400 [24047104.001]
  • [Cites] J Tissue Eng Regen Med. 2008 Oct;2(7):445-9 [18792424.001]
  • [Cites] Cytometry A. 2010 Jan;77(1):22-30 [19852056.001]
  • [Cites] Biomaterials. 2010 Nov;31(31):8012-21 [20674000.001]
  • [Cites] Expert Rev Ophthalmol. 2010 Oct;5(5):645-661 [21436959.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4316-22 [17003421.001]
  • [Cites] PLoS One. 2013 Jul 26;8(7):e69175 [23922689.001]
  • [Cites] Cytotherapy. 2006;8(4):315-7 [16923606.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9523-8 [15983386.001]
  • [Cites] Am J Ophthalmol. 2007 Jan;143(1):178-80 [17188066.001]
  • [Cites] Dermatol Surg. 2001 Sep;27(9):819-26 [11553171.001]
  • [Cites] Ophthalmology. 2006 Oct;113(10):1765-72 [16905193.001]
  • [Cites] J Cell Biochem. 2011 Apr;112(4):993-1002 [21308743.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Mar;37(4):645-55 [8595965.001]
  • [Cites] Tissue Eng Part A. 2008 Jul;14(7):1275-82 [18433313.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Apr 25;52(5):2817-24 [21220557.001]
  • [Cites] Acta Derm Venereol. 2012 Jan;92(1):16-23 [21879248.001]
  • [Cites] Ann Plast Surg. 2008 Mar;60(3):306-22 [18443514.001]
  • [Cites] Transplantation. 2001 Nov 15;72(9):1478-85 [11707733.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):289-96 [17008425.001]
  • [Cites] Haemostasis. 1986;16(3-4):258-72 [3530901.001]
  • [Cites] J Tissue Eng Regen Med. 2010 Jan;4(1):38-44 [19813216.001]
  • [Cites] N Engl J Med. 2010 Jul 8;363(2):147-55 [20573916.001]
  • [Cites] Brain Res Dev Brain Res. 2003 Oct 10;145(1):141-9 [14519500.001]
  • [Cites] Stem Cells. 2010 Mar 31;28(3):597-610 [20014040.001]
  • [Cites] Nature. 1971 Feb 19;229(5286):560-1 [4925352.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1995-2005 [17495107.001]
  • [Cites] Cell Res. 2007 Jan;17(1):26-36 [17211449.001]
  • [Cites] Differentiation. 2007 Jan;75(1):12-23 [17244018.001]
  • [Cites] Histochemistry. 1988;89(4):369-77 [2457569.001]
  • [Cites] Exp Eye Res. 2015 Sep;138:70-9 [26142953.001]
  • [Cites] ANZ J Surg. 2009 Apr;79(4):235-44 [19432707.001]
  • [Cites] Cytometry A. 2013 Jan;83(1):134-40 [23184564.001]
  • [Cites] Arch Ophthalmol. 2007 Oct;125(10):1337-44 [17923540.001]
  • [Cites] Cornea. 2009 Feb;28(2):233-6 [19158575.001]
  • [Cites] Curr Eye Res. 2014 Jun;39(6):541-52 [24405104.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):279-86 [22167096.001]
  • [Cites] Exp Mol Med. 2013 Nov 15;45:e54 [24232253.001]
  • [Cites] Int J Stem Cells. 2014 Nov;7(2):118-26 [25473449.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Jul 01;52(7):4734-41 [21357396.001]
  • [Cites] Blood. 2013 Apr 11;121(15):2891-901 [23412095.001]
  • [Cites] BMC Med Genomics. 2015 Jul 24;8:41 [26205789.001]
  • (PMID = 29020119.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / RNA, Messenger; 0 / TP63 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


6. Zhou Y, Wei Y, Wang L, Wang X, Du X, Sun Z, Dong N, Chen X: Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol; 2011;10:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease.
  • BACKGROUND: Disorders of endocrine substances in epicardial adipose tissue are known causes of coronary artery disease (CAD).
  • Adiponectin is associated with cardiovascular disease.
  • However, expression of adiponectin in epicardial adipose tissue and its function in CAD pathogenesis is unclear.
  • This study investigates adiponectin expression in epicardial adipose tissue in CAD patients.
  • METHODS: Vessels or adipose tissue samples collected from CAD patients and non-CAD controls were examined after immunochemical staining.
  • Adiponectin, cytokines of interleukin-6 (IL-6) and necrosis factor-α (TNF-α) and toll-like receptor 4 (TLR4) expression level in adipose tissue were measured using real-time quantitative RT-PCR.
  • RESULTS: Histological examination revealed increased macrophage infiltration into epicardial adipose tissue of CAD patients.
  • Decreased adiponectin displayed by real-time quantitative RT-PCR was associated with enhanced cytokines of IL-6 and TNF-α or TLR4 expression level in epicardial adipose tissue, suggesting decreased circulating adiponectin may be useful as a more sensitive predictor for coronary atherosclerosis than routine laboratory examinations.
  • CONCLUSIONS: Endocrine disorders in epicardial adipose tissue are strongly linked to CAD, and adiponectin has a protective effect by inhibiting macrophage-mediated inflammation.
  • [MeSH-major] Adipose Tissue / immunology. Coronary Artery Disease / blood. Coronary Artery Disease / immunology. Inflammation Mediators / metabolism. Monocytes / immunology
  • [MeSH-minor] Adiponectin / blood. Adiponectin / genetics. Aged. Aged, 80 and over. Apoptosis. Case-Control Studies. Cells, Cultured. China. Down-Regulation. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Gene Expression Profiling / methods. Humans. Interleukin-6 / genetics. Interleukin-6 / metabolism. Macrophages / immunology. Middle Aged. Pericardium. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Toll-Like Receptor 4 / genetics. Toll-Like Receptor 4 / metabolism. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Atherosclerosis. 2000 Feb;148(2):209-14 [10657556.001]
  • [Cites] Int J Cardiol. 2010 Sep 24;144(1):160-3 [19174315.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2005-10 [11172066.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1876-83 [12031976.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):37487-91 [12138120.001]
  • [Cites] Blood. 1993 Mar 15;81(6):1607-13 [7680921.001]
  • [Cites] J Biol Chem. 1994 Apr 15;269(15):11425-34 [7512565.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] Endocrinology. 1995 May;136(5):2143-9 [7720663.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):26746-9 [7592907.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Apr 16;221(2):286-9 [8619847.001]
  • [Cites] Mol Med. 1996 Sep;2(5):568-82 [8898373.001]
  • [Cites] J Biochem. 1996 Oct;120(4):803-12 [8947845.001]
  • [Cites] Diabetes. 1997 May;46(5):860-7 [9133556.001]
  • [Cites] Gene. 1999 Mar 18;229(1-2):67-73 [10095105.001]
  • [Cites] Pharmacol Ther. 2005 Aug;107(2):198-211 [15907343.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2005 Oct;2(10):536-43 [16186852.001]
  • [Cites] Cardiovasc Diabetol. 2006;5:1 [16412224.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):45-9 [17210129.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):2012-30 [17466567.001]
  • [Cites] Can J Cardiol. 2007 Oct;23 Suppl B:23B-31B [17932584.001]
  • [Cites] Int J Obes (Lond). 2008 Feb;32(2):268-74 [17878891.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(5):821-36 [18201922.001]
  • [Cites] Curr Opin Cardiol. 2008 Nov;23(6):591-8 [18830075.001]
  • [Cites] Diabetologia. 2009 Feb;52(2):318-28 [19052722.001]
  • [Cites] Horm Metab Res. 2009 Mar;41(3):227-31 [19003726.001]
  • [Cites] Circ J. 2009 Apr;73(4):608-14 [19261992.001]
  • [Cites] Obes Rev. 2009 May;10(3):269-79 [19389061.001]
  • [Cites] Thromb Haemost. 2009 Jun;101(6):1006-11 [19492140.001]
  • [Cites] Cardiovasc Diabetol. 2010;9:26 [20573249.001]
  • [Cites] Cardiovasc Diabetol. 2010;9:29 [20604967.001]
  • [Cites] Cardiovasc Diabetol. 2010;9:50 [20836881.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):307-12 [11201732.001]
  • (PMID = 21226932.001).
  • [ISSN] 1475-2840
  • [Journal-full-title] Cardiovascular diabetology
  • [ISO-abbreviation] Cardiovasc Diabetol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / IL6 protein, human; 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / RNA, Messenger; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC3032658
  •  go-up   go-down


7. Fuentes-Julián S, Arnalich-Montiel F, Jaumandreu L, Leal M, Casado A, García-Tuñon I, Hernández-Jiménez E, López-Collazo E, De Miguel MP: Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome. PLoS One; 2015;10(3):e0117945
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipose-derived mesenchymal stem cell administration does not improve corneal graft survival outcome.
  • The effect of local and systemic injections of mesenchymal stem cells derived from adipose tissue (AD-MSC) into rabbit models of corneal allograft rejection with either normal-risk or high-risk vascularized corneal beds was investigated.
  • Based on our results, local or systemic treatment with AD-MSCs to prevent corneal rejection in rabbit corneal models at normal or high risk of rejection does not increase survival but rather can increase inflammation and neovascularization and break the innate ocular immune privilege.
  • [MeSH-major] Adipose Tissue / cytology. Graft Survival / physiology. Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / cytology
  • [MeSH-minor] Animals. Cell Differentiation. Coculture Techniques. Cornea / pathology. Corneal Diseases / pathology. Corneal Diseases / therapy. Corneal Transplantation. Cytokines / metabolism. Female. Humans. Immunohistochemistry. Male. Rabbits. T-Lymphocytes / cytology. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. Transplantation, Heterologous. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Plast Surg. 1999 Oct;26(4):587-603, viii [10553215.001]
  • [Cites] Mol Cell. 2000 Sep;6(3):683-92 [11030347.001]
  • [Cites] Tissue Eng. 2001 Apr;7(2):211-28 [11304456.001]
  • [Cites] Exp Hematol. 2002 Jan;30(1):42-8 [11823036.001]
  • [Cites] Ophthalmology. 2003 Jul;110(7):1396-402 [12867398.001]
  • [Cites] Exp Hematol. 2003 Oct;31(10):890-6 [14550804.001]
  • [Cites] Klin Wochenschr. 1987 Sep 1;65(17):803-11 [3309456.001]
  • [Cites] Transplantation. 2005 Apr 27;79(8):964-8 [15849551.001]
  • [Cites] Blood. 2005 May 15;105(10):4120-6 [15692068.001]
  • [Cites] Osteoarthritis Cartilage. 2005 Oct;13(10):845-53 [16129630.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2570-7 [16293599.001]
  • [Cites] Mol Cell Biochem. 2006 Apr;285(1-2):69-78 [16477377.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1390-7 [16732175.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4817-24 [16493000.001]
  • [Cites] Transplantation. 2006 Jun 15;81(11):1589-95 [16770249.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3339-44 [16877400.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2114-20 [16690970.001]
  • [Cites] Transplantation. 2007 May 27;83(10):1401-3 [17519795.001]
  • [Cites] Pediatr Transplant. 2007 Nov;11(7):814-7 [17910665.001]
  • [Cites] Transplant Proc. 2007 Dec;39(10):3404-8 [18089393.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1598-608 [18209056.001]
  • [Cites] Stem Cells. 2008 Feb;26(2):570-9 [18065394.001]
  • [Cites] Cell Stem Cell. 2008 Feb 7;2(2):141-50 [18371435.001]
  • [Cites] Lancet. 2008 May 10;371(9624):1579-86 [18468541.001]
  • [Cites] Cell Res. 2008 Aug;18(8):846-57 [18607390.001]
  • [Cites] J Immunol. 2008 Sep 15;181(6):3933-46 [18768848.001]
  • [Cites] Int Ophthalmol. 2008 Jun;28(3):209-22 [17673946.001]
  • [Cites] Stem Cells. 2009 Apr;27(4):942-8 [19353522.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6576-83 [19398717.001]
  • [Cites] Diabetes. 2009 Aug;58(8):1797-806 [19509016.001]
  • [Cites] Am J Transplant. 2009 Aug;9(8):1760-72 [19563344.001]
  • [Cites] Stem Cells. 2009 Aug;27(8):1954-62 [19544427.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2632-8 [19654411.001]
  • [Cites] Vet Ophthalmol. 2009 Nov-Dec;12 Suppl 1:35-40 [19891650.001]
  • [Cites] Eye (Lond). 2009 Nov;23(11):2063-70 [19151659.001]
  • [Cites] Stem Cells. 2009 Nov;27(11):2865-74 [19750539.001]
  • [Cites] Ocul Immunol Inflamm. 2010 Jun;18(3):162-71 [20482389.001]
  • [Cites] Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16766-71 [25385603.001]
  • [Cites] Stem Cells Dev. 2010 May;19(5):693-706 [20067407.001]
  • [Cites] Transplantation. 2010 Dec 27;90(12):1312-20 [21042238.001]
  • [Cites] Transplantation. 2010 Dec 27;90(12):1366-73 [21076379.001]
  • [Cites] Biol Blood Marrow Transplant. 2011 Apr;17(4):534-41 [20457269.001]
  • [Cites] Cell Transplant. 2011;20(2):205-16 [20719083.001]
  • [Cites] Mol Med. 2011;17(7-8):697-708 [21365122.001]
  • [Cites] Plast Reconstr Surg. 2011 Dec;128(6):661e-72e [22094768.001]
  • [Cites] Curr Mol Med. 2012 Jun;12(5):574-91 [22515979.001]
  • [Cites] Exp Eye Res. 2012 Sep;102:44-9 [22800963.001]
  • [Cites] Mol Ther. 2012 Nov;20(11):2143-52 [22929658.001]
  • [Cites] Cell Transplant. 2011;20(10):1547-59 [21396164.001]
  • [Cites] Cell Transplant. 2013;22(1):41-54 [22472599.001]
  • [Cites] Stem Cells Dev. 2013 Jun 15;22(12):1789-801 [23339531.001]
  • [Cites] Cell Stem Cell. 2013 Oct 3;13(4):392-402 [24094322.001]
  • [Cites] Eur J Clin Invest. 2014 Jan;44(1):83-92 [24350923.001]
  • (PMID = 25730319.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ PMC4346399
  •  go-up   go-down


8. Gouranton E, Romier B, Marcotorchino J, Tourniaire F, Astier J, Peiretti F, Landrier JF: Visfatin is involved in TNFα-mediated insulin resistance via an NAD(+)/Sirt1/PTP1B pathway in 3T3-L1 adipocytes. Adipocyte; 2014 Jul 1;3(3):180-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor α (TNFα) is a well-known mediator of inflammation in the context of obesity in adipose tissue.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25068084.001).
  • [ISSN] 2162-3945
  • [Journal-full-title] Adipocyte
  • [ISO-abbreviation] Adipocyte
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4110094
  • [Keywords] NOTNLM ; NAD / TNF / adipocytes / insulin resistance / sirtuin / visfatin
  •  go-up   go-down


9. Duong MN, Cleret A, Matera EL, Chettab K, Mathé D, Valsesia-Wittmann S, Clémenceau B, Dumontet C: Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res; 2015;17:57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.
  • INTRODUCTION: Trastuzumab has been used in the treatment of human epidermal growth factor receptor 2 (HER2)-expressing breast cancer, but its efficacy is limited by de novo or acquired resistance.
  • Although many mechanisms have been proposed to explain resistance to trastuzumab, little is known concerning the role of the tumor microenvironment.
  • Given the importance of antibody-dependent cellular cytotoxicity (ADCC) in the antitumor effect of trastuzumab and the abundance of adipose tissue in the breast, we investigated the impact of adipocytes on ADCC.
  • The inhibition of ADCC was not due to titration or degradation of the antibody.
  • We found that adipose cells decreased the secretion of interferon-γ by natural killer cells, but did not alter natural killer cells' cytotoxicity.
  • Importantly, breast tumors grafted next to lipomas displayed resistance to trastuzumab in mouse xenograft models.
  • CONCLUSIONS: Collectively, our findings underline the importance of adipose tissue in the resistance to trastuzumab and suggest that approaches targeting the adipocyte-cancer cell crosstalk may help sensitize cancer cells to trastuzumab-based therapy.
  • [MeSH-major] Adipocytes / metabolism. Antibody-Dependent Cell Cytotoxicity / immunology. Breast Neoplasms / immunology. Breast Neoplasms / metabolism. Drug Resistance, Neoplasm. Trastuzumab / immunology. Trastuzumab / pharmacology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Culture Media, Conditioned. Female. Humans. Induced Pluripotent Stem Cells / cytology. Induced Pluripotent Stem Cells / metabolism. Killer Cells, Natural / immunology. Killer Cells, Natural / metabolism. Mammary Neoplasms, Animal. Mice. Tumor Burden. Xenograft Model Antitumor Assays


10. Justo ML, Claro C, Zeyda M, Stulnig TM, Herrera MD, Rodríguez-Rodríguez R: Rice bran prevents high-fat diet-induced inflammation and macrophage content in adipose tissue. Eur J Nutr; 2016 Sep;55(6):2011-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rice bran prevents high-fat diet-induced inflammation and macrophage content in adipose tissue.
  • BACKGROUND: The inflammatory process associated with obesity mainly arises from white adipose tissue (WAT) alterations.
  • Our aim was to determine the potential of a rice bran enzymatic extract (RBEE)-supplemented diet in the prevention of metabolic, biochemical and functional adipose tissue and macrophage changes associated with a diet-induced obesity (DIO) in mice.
  • CONCLUSIONS: RBEE-supplemented diet attenuated insulin resistance, dyslipidemia and morphological and functional alterations of adipose tissue in DIO mice.
  • [MeSH-major] Adipose Tissue, White / metabolism. Diet, High-Fat / adverse effects. Dietary Fiber / administration & dosage. Inflammation / diet therapy. Macrophages / metabolism. Oryza / chemistry
  • [MeSH-minor] Adipocytes. Adiponectin / metabolism. Animals. Biomarkers / blood. Cholesterol / blood. Dyslipidemias / diet therapy. Dyslipidemias / etiology. Insulin / blood. Insulin Resistance. Interleukin-1beta / blood. Interleukin-6 / blood. Male. Mice. Mice, Inbred C57BL. Obesity / diet therapy. Obesity / etiology. PPAR gamma / metabolism. Receptors, Cell Surface / metabolism. Triglycerides / blood. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] Plant Foods Hum Nutr. 2013 Sep;68(3):274-8 [23907589.001]
  • [Cites] J Nutr Biochem. 2013 Aug;24(8):1453-61 [23465593.001]
  • [Cites] Curr Vasc Pharmacol. 2013 Nov;11(6):954-67 [24168446.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2014 May;24(5):524-31 [24361072.001]
  • [Cites] Atherosclerosis. 2002 Mar;161(1):199-207 [11882333.001]
  • [Cites] Metabolism. 2014 Apr;63(4):542-53 [24467915.001]
  • [Cites] Food Chem Toxicol. 2005 May;43(5):747-53 [15778015.001]
  • [Cites] Obesity (Silver Spring). 2009 Jul;17 (7):1340-7 [19553924.001]
  • [Cites] Annu Rev Physiol. 2010;72:219-46 [20148674.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45777-84 [12952969.001]
  • [Cites] ISRN Inflamm. 2013 Dec 22;2013:139239 [24455420.001]
  • [Cites] J Oleo Sci. 2012;61(7):369-75 [22790167.001]
  • [Cites] Life Sci. 2013 May 20;92(17-19):938-49 [23567805.001]
  • [Cites] J Am Coll Nutr. 2010 Jun;29(3 Suppl):289S-301S [20823489.001]
  • [Cites] BMC Cancer. 2003 Oct 01;3:25 [14521714.001]
  • [Cites] Curr Top Med Chem. 2011;11(14):1847-53 [21506933.001]
  • [Cites] J Clin Biochem Nutr. 2012 Nov;51(3):235-40 [23170053.001]
  • [Cites] Mediators Inflamm. 2010;2010:359732 [20508722.001]
  • [Cites] Annu Rev Immunol. 2011;29:415-45 [21219177.001]
  • [Cites] Nutrients. 2013 Feb 06;5(2):468-77 [23389305.001]
  • [Cites] Nutrition. 2014 Apr;30(4):466-72 [24607304.001]
  • [Cites] Obesity (Silver Spring). 2012 May;20(5):932-8 [22240722.001]
  • [Cites] Science. 2013 Jan 11;339(6116):172-7 [23307735.001]
  • [Cites] Nat Rev Immunol. 2008 Dec;8(12):923-34 [19029988.001]
  • [Cites] Br J Nutr. 2007 Jan;97(1):67-76 [17217561.001]
  • [Cites] Lipids. 2003 Feb;38(2):165-70 [12733749.001]
  • [Cites] PPAR Res. 2012;2012:318613 [23251142.001]
  • [Cites] Br J Pharmacol. 2008 Jun;154(4):812-24 [18536734.001]
  • [Cites] Annu Rev Pathol. 2007;2:31-56 [18039092.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2009 Jun;117(6):241-50 [19358089.001]
  • [Cites] Am J Hypertens. 2007 Jul;20(7):728-34 [17586406.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):175-84 [17200717.001]
  • [Cites] J Nutr Biochem. 2007 Feb;18(2):105-12 [16713234.001]
  • [Cites] Mol Med. 2008 Mar-Apr;14(3-4):222-31 [18235842.001]
  • [Cites] Pharm Biol. 2012 Feb;50(2):208-24 [22235888.001]
  • [Cites] Diabetologia. 2006 Jan;49(1):132-40 [16362280.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1116-20 [17515919.001]
  • [Cites] Annu Rev Biochem. 2008;77:289-312 [18518822.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):213-5 [17229948.001]
  • [Cites] Crit Rev Food Sci Nutr. 2011 Oct-Nov;51(9):816-27 [21888532.001]
  • [Cites] Eur J Nutr. 2013 Mar;52(2):789-97 [22661284.001]
  • [Cites] Phytother Res. 2001 Jun;15(4):277-89 [11406848.001]
  • (PMID = 26266932.001).
  • [ISSN] 1436-6215
  • [Journal-full-title] European journal of nutrition
  • [ISO-abbreviation] Eur J Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Biomarkers; 0 / Emr1 protein, mouse; 0 / Insulin; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / PPAR gamma; 0 / Receptors, Cell Surface; 0 / Triglycerides; 0 / Tumor Necrosis Factor-alpha; 97C5T2UQ7J / Cholesterol
  • [Keywords] NOTNLM ; Adipose tissue / DIO mice / Inflammation / Macrophage polarization / Obesity / Rice bran / γ-Oryzanol
  •  go-up   go-down






Advertisement